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Background
The relationship between depression and sexual behaviour
among men who have sex with men (MSM) is poorly
understood.
Aims
To investigate prevalence and correlates of depressive
symptoms (Patient Health Questionnaire-9 score ≥10) and
the relationship between depressive symptoms and sexual
behaviour among MSM reporting recent sex.
Method
The Attitudes to and Understanding of Risk of Acquisition
of HIV (AURAH) is a cross-sectional study of UK
genitourinary medicine clinic attendees without diagnosed
HIV (2013–2014).
Results
Among 1340 MSM, depressive symptoms (12.4%) were
strongly associated with socioeconomic disadvantage and
lower supportive network. Adjusted for key sociodemographic
factors, depressive symptoms were associated with measures
of condomless sex partners in the past 3 months
(≥2 (prevalence ratio (PR) 1.42, 95% CI 1.17–1.74; P=0.001),
unknown or HIV-positive status (PR 1.43, 95% CI 1.20–1.71;
P<0.001)), sexually transmitted infection (STI) diagnosis
(PR 1.46, 95% CI 1.19–1.79; P<0.001) and post-exposure
prophylaxis use in the past year (PR 1.83, 95% CI 1.33–2.50;
P<0.001).
Conclusions
Management of mental health may play a role in HIV and STI
prevention.
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HIV transmission is ongoing among gay, bisexual and other men
who have sex with men (MSM) in the UK, with 3320 new diagnoses
in 2015.1 AlthoughHIV prevention has been a public health priority
amongMSM in the UK and Europe, mental health has not generally
been a focus of European studies of HIV and sexually transmitted
infection (STI) risk and prevention among MSM. The potential role
of depression in sexual health and transmission of HIV is not well
understood.
Quantitative link in epidemiological literature
Assessment of the association between depression and condomless
sex (CLS) in epidemiological studies may be problematic, because
individuals with depressive symptoms may be more likely to engage
in CLS or, on the other hand, more likely to have lowered libido and
less interest in sex. The direction in which the association operates
may be a function of a number of factors including the severity
of the symptoms or the type of coping mechanism employed by
the individual.2 Such opposing trends could result in an observed
overall lack of association. The only meta-analysis that has examined
this association among MSM included studies conducted up to 1999.2
Findings across studies were inconsistent. In combined estimates, there
was no significant relationship between depression and measures of
CLS. Stratifying by sample population (MSM, substance users or other)
and HIV status did not significantly moderate the association. A
number of studies of MSM and HIV-negative MSM published since
1999 have reported a significant relationship between depressive
symptoms and CLS in unadjusted analysis3–6 and after adjusting for
sociodemographic, lifestyle, psychosocial and/or sexual behaviour
measures.7–14 However, some studies have failed to find a relationship
in unadjusted analysis15–20 or after adjusting for sociodemographic,
lifestyle and psychosocial measures.21 The association and magnitude
of effect may vary according to the setting and specific sample of
MSMunder study. The vastmajority of studies have been conducted in
the USA. To date, only two relatively small European studies have
investigated the relationship between depression and CLS among
MSM, both finding that depressive symptoms were associated with
CLS measures.3,5
Theoretical link in self-regulation and
coping literature
It has been suggested that some individuals may engage in CLS, not
because they lack information or intentions to be safe, but because
sexuality is a non-rational emotionally charged area. A number of
factors may have an impact on non-rationality of sexual risk
behaviour, such as psychological symptoms (e.g. depression may
distort perceptions of personal vulnerability) and recreational drug
use (which may lead to increased sexual arousal and disinhibition).
However, it is also possible that any such associations are bi-
directional; experiences of sexual risk may increase vulnerability to
symptoms of depression and drug use.22
Cognitive escape is a theoretical process whereby individuals
turn their attention away from threatening cues, completely or
127
BJPsych Open (2017)
3, 127–137. doi: 10.1192/bjpo.bp.116.003574
partially escaping from personal self-awareness. There are two
potential pathways through which cognitive escape might lead to
CLS. The first is fatalistic beliefs about HIV, the notion that
acquiring HIV is inevitable. The second is ‘determination’ to perceive
oneself to be at low risk, despite evidence to the contrary.23 Individuals
with depression have an increased propensity to engage in escapism,
characterised by fatalistic beliefs, as a coping strategy.7,22 The
association between depression and CLS may also be due to the
tendency of individuals with depressive symptoms to experience low
self-efficacy. The principle of self-efficacy, as conceptualised in
social cognitive theory, is that regardless of one’s attitude, action
(e.g. ensuring condom use during sex) requires additional con-
fidence in one’s ability to produce a certain outcome (e.g. sexual
safety).24 Conceptually, cognitive escape and self-efficacy are linked.
Low self-efficacy is thought to make escape tendencies more likely.
It is possible that depression may lower one’s perceived ability to
exercise self-protective control in sexual situations where this is
desired (lowered self-efficacy for sexual safety) and lead to cognitive
escape.7 Recreational drug use may also play a role in these
relationships. In addition to any direct effect on autonomic or
central nervous system mechanisms, substances may be used
strategically to induce a state of cognitive release in sexual settings.
Men with depressive symptoms may be more likely to engage in
recreational drug use, perhaps as a form of self-medication.22
Study objectives
This study uses data from the Attitudes to and Understanding
of Risk of Acquisition of HIV (AURAH) Study of individuals
attending genitourinary medicine (GUM) clinics across the UK.
It investigates, among HIV-negative or unknown status MSM
who reported recent sex: (1) the prevalence of depressive symptoms
and the association with sociodemographic and lifestyle factors;
(2) the relationship of depressive symptoms with CLS and other
sexual behaviour measures, and the potential confounding effect
of recreational drug use; (3) the association between depressive
symptoms andmeasures of self-efficacy for sexual safety; and (4) the
prevalence of treatment for depression, and association of treated
depression with sexual behaviour.
Men who did not report any sex in the past 3 months were
excluded from this analysis, because depressionmay also be linked to a
lack of sexual activity,2 and it was of particular interest to compare
those having condom-protected sex with those having CLS.
Method
AURAH Study is a cross-sectional, self-administered questionnaire
study in individuals attending 20 GUM clinics across the UK from
June 2013 to November 2014.25 Individuals aged 18 years or over
without diagnosed HIV were eligible for inclusion. A total of 4380
eligible participants were approached over the study period, of
whom 2630 completed the questionnaire (response rate: 60%). The
confidential, self-administered questionnaire included questions on
sociodemographics, health, lifestyle and sexual behaviour.
Men were classified as MSM if they met at least one of the
following criteria: (1) reported being gay or bisexual (including
other plurisexual identity labels: pansexual, omnisexual, open or
queer, i.e. identities that are not explicitly based on attractions to
one sex or gender26), (2) reported anal sex with a man in the past
3 months or (3) reported having disclosed to their family, friends or
workmates as being gay, bisexual and/or attracted to men.
Clinically significant depressive symptoms
The Patient Health Questionnaire-9 (PHQ-9) was used to measure
the prevalence of depressive symptoms.27 A score of ≥10 was con‐
sidered to indicate clinically significant depressive symptoms; details
given in Box 1. The score was further classified in terms of severity
of depressive symptoms: moderate (10–14), moderately severe
(15–19) and severe (20–27). In addition, participants were asked
whether they were receiving medical treatment or therapy for
depression.
Sexual behaviour measures
The questionnaire included questions about anal sex with men, and
vaginal or anal sex with women in the past 3 months, and sex
without a condom. Four measures of CLS (anal or vaginal) were
defined: (1) CLS with one or more partners, (2) CLS with two or
more partners, (3) CLS with unknown and/or HIV-positive status
partner(s) (men who reported no CLS partners of unknown HIV
status, and only one HIV positive CLS partner who was a long-term
partner and with whom they ‘thought the risks of catching HIV
were low because their partner was taking ART’ were not counted)
and (4) receptive CLS with unknown HIV-status partner(s). All
reports of CLS were included regardless of the partner’s gender.
Participants were asked whether they had been diagnosed with an
STI in the past year. STI diagnosis was defined as report of one of
four bacterial infections: gonorrhoea, chlamydia, syphilis or lympho-
granuloma venereum (LGV). Furthermore, participants were asked
whether they had taken antiretroviral drugs after CLS to reduce the risk
of becoming infected with HIV, post-exposure prophylaxis (PEP), in
the past year. The final two measures considered concerned partner
numbers: reporting 11 or more new sexual partners in the past year
and reporting group sex (sex with more than one other person on the
same occasion) in the past 3 months.
Measures of self-efficacy for sexual safety
The questionnaire included a number of statements on attitudes
towards condom use, with response options: strongly agree, tend
to agree, undecided or no opinion or not relevant to me, tend to
disagree, strongly disagree. The following statement was used to
measure self-efficacy: ‘I feel confident that, if I want to, I can make
sure a condom is used during sex with any partner, in any situation’.
Strong agreement with this statement was considered to indicate
high self-efficacy for sexual safety. Agreement (‘strong’ or ‘tend to’)
with the following statement was considered to indicate difficulty in
negotiating condom use: ‘I find it difficult to discuss condom use
with any new sexual partner’.
Men were also asked reasons for non-condom use in the past
3 months, for which one or more of the following options could be
Box 1 The Patient Health Questionnaire 9-item scale (PHQ-9)27
for depressive symptoms
‘Over the past 2 weeks, how often have you been bothered by any of the
following problems?’
1 Little interest or pleasure in doing things.
2 Feeling down, depressed or hopeless.
3 Trouble falling or staying asleep, or sleeping too much.
4 Feeling tired or having little energy.
5 Poor appetite or overeating.
6 Feeling bad about yourself – or that you are a failure or have let
yourself or your family down.
7 Trouble concentrating on things, such as reading the newspaper or
watching television.
8 Moving or speaking so slowly that other people could have noticed/
being so restless that it is hard to sit still.
9 Thoughts that you would be better off dead or of hurting yourself in
some way.
Response options:
Not at all (coded as 0)
Several days (coded as 1)
More than half the days (coded as 2)
Nearly every day (coded as 3)
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chosen: ‘Didn’t think about using a condom or did not have a
condom’, ‘Don’t like using condoms or it’s more enjoyable/close
without a condom’, ‘My partner didn’t want to use a condom’, ‘Felt
unable to discuss condom use’, ‘Got carried away or was under the
influence of alcohol or drugs’ and ‘Difficult for me/partner to keep
erection or ejaculate when using a condom’.
Statistical analysis
Associations were assessed by χ2 tests, χ2 tests for trend and Fisher’s
exact test (when expected numbers were small) for univariable
analysis, and modified Poisson regression with a robust variance
estimator to produce adjusted prevalence ratios (PRs) for multi-
variable analysis.28 PRs were chosen for their ease of interpretation. It
should be noted that, where the prevalence of the different outcome
measures differ, it is not appropriate to compare the magnitude of
PRs for depression across these different outcome measures.
For assessment of the relationship of sociodemographic and
lifestyle factors with depressive symptoms, associations are presented
unadjusted, and adjusted for the following socio-demographic factors:
age group (<25, 25–29, 30–39 or ≥40 years), country of birth (UK
born or non-UK born/missing), self-reported sexual identity (gay or
bisexual/straight), university education (yes or no/missing), ongoing
relationship (yes or no/missing) and study region (London, South or
other – see Table 1 footnote for definition).
For assessment of the relationship of depressive symptoms
with sexual behaviour measures, associations are presented
unadjusted, adjusted for the above sociodemographic factors and
finally adjusted for the above sociodemographic factors plus
current smoking (yes or no/missing), higher risk alcohol con-
sumption (yes or no/missing; see Table 1 for definition) and
number of recreational drugs used in the past 3 months (none, 1,
2–4 or ≥5), to assess the extent to which the associations were
attenuated when accounting for smoking, drug and alcohol use.
Measures of self-efficacy for sexual safety were hypothesised
a priori to be on the casual pathway between depressive symptoms
and sexual risk behaviour. The association of depressive symptoms
with self-efficacy measures and the association of self-efficacy
measures with sexual behaviour measures were investigated.
Finally, the prevalence of treatment for depression was assessed,
and the associations with sexual behaviour measures were assessed
according to the presence or absence of depressive symptoms and
treatment for depression.
The proportion of missing values was <5% for all variables used
in analyses; missing values were incorporated into specific cate-
gories for some variables (see Table 1). All analyses were performed
by STATA statistical software29 and reported according to the
STROBE guidelines.30 Several sensitivity analyses were undertaken:
(1) adjusting for age grouped into six categories (<25, 25–29, 30–34,
35–39, 40–44 or ≥45 years), (2) adjusting for age as a continuous
variable, (3) excluding missing values when defining each variable
and (4) assessing the association between depressive symptoms and
sexual behaviour measures only among men who reported anal sex
with a man in the past 3 months. In each case, the findings were very
similar to the main analysis (results not shown).
Ethical approval
The research protocol and all versions of the study documents
were approved by the designated research ethics committee
(NRES committee London-Hampstead, ref: 13/LO/0246).
Results
In total, 2630 individuals participated in the AURAH Study, of
whom 1484 were defined as MSM. The current analysis is based
on 1340 MSM who reported anal or vaginal sex in the past 3
months. Of these, 1238 (92.4%) reported anal sex with men only,
66 (4.9%) reported sex with both men and women and 36 (2.7%)
reported sex with women only in the past 3 months. Eighty-nine
per cent of the 1340 men identified as gay, 9.5% as bisexual or
another plurisexual identity label and 1.4% as straight. Eighty-two
per cent of men were of White ethnicity; median age was 31 years.
Overall, 57% were born in the UK, 67% had a university degree
and 76% were attending a clinic in London (Table 1).
Depressive symptoms
The prevalence of depressive symptoms (PHQ-9 score ≥10) was
12.4% (166 of 1340). Of these 166 men, 55% had moderate
depressive symptom severity, 30.1% had moderately severe
symptoms and 15.1% had severe symptoms of depression.
Correlates of depressive symptoms
In unadjusted analysis, depressive symptoms were strongly associated
with indicators of lower socioeconomic status (financial hardship,
non-employment, rented or unstable housing and non-university
education), and there was an exceptionally strong association with
lower reported levels of a supportive network. Depressive symptoms
were also associated with younger age, bisexual (or other plurisexual)
identity, Midlands or Yorkshire or Humber region of recruitment,
disclosing being MSM to few or no work colleagues, smoking, higher-
risk drinking and greater number of recreational drugs used (Table 1).
After adjusting for key sociodemographic factors, these associations
remained, with some attenuation in the magnitude of effect, with the
exception of study region and smoking, which were no longer
significantly associated with depressive symptoms (Table 1).
Sexual behaviour measures
Overall, 63.7% (n=853) of men reported CLS in the past 3 months.
Of these, 91.7% (n=782) had CLS with men only, 3.9% (n=33) had
CLS with both men and women and 4.5% (n=38) had CLS with
women only. The prevalence of CLS and other sexual behaviour
measures is presented in Table 2. The prevalence of high self-
efficacy was 67.2% (n=900) and 10.6% (n=142) for difficulty
negotiating condom use. Among the 853 men who reported CLS,
the reasons indicated for non-condom use (788 total responses)
were as follows: got carried away or under the influence of alcohol
or drugs (n=369; 43.3%), don’t like or more enjoyable without
(n=353; 41.4%), their or their partner’s difficulty in keeping an
erection or ejaculating (n=205; 24.0%), partner not wanting to
(n=147; 17.2%), didn’t think about it or didn’t have (n=131;
15.4%), and felt unable to discuss (n=37; 4.3%).
Relationship between depressive symptoms and
sexual behaviour
Men with depressive symptoms (n=166) were more likely than
those without (n=1174) to report measures of CLS partners in the
past 3 months: ≥1 (74.7% v. 62.1%), ≥2 (44.6% v. 30.4%), unknown
and/or HIV-positive status (50.6% v. 33.2%), receptive unknown
status (22.9% v. 12.7%). They were also more likely to report
diagnosed bacterial STI (42.2% v. 30.1%) and PEP use (23.5% v.
14.3%) in the past year (P<0.01 for all, χ2 tests). The prevalence of
CLS with one or more partners was 70.3% among men with
moderate depressive symptom severity, 78.0% among men with
moderately severe symptoms and 84.0% among men with severe
symptoms of depression.
After adjusting for key sociodemographic factors, depressive
symptoms were associated with all measures of CLS partners (≥1
(PR 1.18, 95% CI 1.06−1.30; P=0.002), ≥2 (PR 1.42, 95% CI 1.17–
1.74; P=0.001), unknown and/or HIV-positive status (PR 1.43,
95% CI 1.20–1.71; P<0.001), receptive unknown status (PR 1.60,
95% CI 1.14–2.24; P=0.006)) and with bacterial STI diagnosis
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(PR 1.46, 95% CI 1.19–1.79; P<0.001) and PEP use (PR 1.83, 95%
CI 1.33–2.50; P<0.001) (Fig. 1). After adjusting additionally for
smoking, alcohol and recreational drug use, most of these associa-
tions were attenuated to some extent, but they remained significant
(Fig. 1). Associations were also apparent among men who had not
taken recreational drugs in the past 3 months (data not shown).
Depressive symptoms were not associated with having 11 or
more new sexual partners in the past year or with group sex in the
past 3 months, in unadjusted or adjusted analyses (Fig. 1).
Self-efficacy for sexual safety: relationship with
depressive symptoms and sexual behaviour
Men with depressive symptoms were less likely to report high self-
efficacy for sexual safety (56.6% v. 68.7%; P=0.002) and more
likely to report difficulty negotiating condom use (18.7% v. 9.5%;
P<0.001) than men without. Adjusted for key sociodemographic
factors, depressive symptoms were inversely associated with self-
efficacy (PR 0.82, 95% CI 0.71–0.94; P=0.006) and were associated
with difficulty negotiating condom use (PR 1.77, 95% CI 1.18–2.63;
P=0.005). These associations remained with some attenuation, after
additional adjustment for smoking, alcohol and recreational drug
use (data not shown).
Men with high self-efficacy were less likely than those without to
report CLS partners: ≥1 (55.7% v. 80.0%), ≥2 (24.3% v. 48.0%),
unknown and/or HIV-positive status (26.9% v. 52.7%), receptive
unknown status (10.3% v. 21.4%) and STI diagnosis (29.2% v.
36.4%), and PEP use (13.6% v. 19.3%); P≤0.01 for all. Men who
reported difficulty negotiating condom use were more likely than
those who did not to report CLS partners: ≥1 (80.3% v. 61.7%), ≥2
(45.8% v. 30.5%), unknown and/or HIV-positive status (55.6% v.
33.0%) and receptive unknown status (23.2% v. 12.9%); P≤0.001 for
all. Adjusted for key sociodemographics (and additionally adjusted
for lifestyle factors), high self-efficacy was associated with lower
prevalence of CLS partners, STI diagnosis and PEP use, but not
high partner numbers or group sex (Fig. 2). Similar, albeit weaker,
associations were found when investigating difficulty negotiating
condom use (Fig. 3).
Among men who reported CLS, men with depressive symptoms
were more likely than those without to report having gotten carried
away or been under the influence of alcohol or drugs (54.8% v. 41.3%;
P=0.005), their or their partner’s difficulty in keeping an erection or
ejaculating with a condom (32.3% v. 22.6%; P=0.020) and their partner
not wanting to use a condom (23.4% v. 16.2%; P=0.050).
Receiving medical treatment or therapy for depression
Overall, the proportion of men who reported receiving treatment
(medicine or therapy) for depression was 9.2% (123 of 1340).
Treatment for depression was reported by 28.9% (n=48) of the
166 men with depressive symptoms and 6.4% (n=75) of the 1174
men without. To more accurately present the prevalence of men
with depression who were receiving treatment, men with either
depressive symptoms (PHQ-9≥10) or who reported receiving
treatment for depression were considered to account for all men
with any evidence of current depression. Among these 241 men,
51.0% (n=123) were receiving treatment for depression.
The prevalence of CLS partner measures, STI diagnosis and PEP
use according to evidence of depression (symptoms and/or treat-
ment) is presented in Table 3. Men with any evidence of current
depression tended to be more likely to report measures of sexual risk
than those without evidence of depression. Adjusted PRs of CLS with
one or more partners, STI diagnosis and PEP use were higher for
men who reported depressive symptoms (with or without treatment)
than for those who reported treatment but no current symptoms.
For the other measures of CLS, prevalence was elevated for all three
depression groups, compared with no depression.
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Clinically significant depressive symptoms
Discussion
AURAH is the largest questionnaire study of sexual behaviour
undertaken among individuals attending GUM clinics in the
UK and one of the first UK studies to assess the association of
depressive symptoms with CLS. Depressive symptoms were
associated with all measures of CLS, including bacterial STI
diagnosis and PEP use, independently of sociodemographic and
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N=1340 MSM reporting anal/vaginal sex (past 3 months) Prevalence ratio associated
with PHQ-9 score ≥10 
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CLS with 2+ partners (past 3 months)
(n=430; 32.1%) 
CLS with unknown/HIV+ partner(s)a
(past 3 months)
(n=474; 35.4%) 
Receptive CLS with unknown status
partner(s) (past 3 months)
(n=187; 14.0%) 
Bacterial STI diagnosis (past year)
(n=423; 31.6%) 
PEP use (past year)
(n=207; 15.5%) 
11+ new sexual partners (past year)
(n=483; 36.0%) 
Group sex (past 3 months)
(n=496; 37.0%) 
PR, prevalence ratio.
P-value by Wald test using 
modified Poisson regression
Unadjusted prevalence ratio (N=1340)
Prevalence ratio adjusted for: age, UK bornb, sexual identityb, university education, ongoing relationship
status, and study region (N=1316) 
Prevalence ratio adjusted for above sociodemographic factors plus smoking, higher-risk drinking, and
number of recreational drugs used (N=1316)
Dependent variable: 
Fig. 1 Unadjusted and adjusted associations of current depressive symptoms on PHQ-9 (≥10) with sexual behaviours among 1340 MSM who
reported anal or vaginal sex in the past 3 months.
CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; STI, sexually transmitted infection.
a. Excludes men who reported no CLS partners of unknown HIV status, and only one HIV positive CLS partner who was a long-term partner and with
whom they ‘thought the risks of catching HIV were low because their partner was taking ART’.
b. The model was ﬁtted to include age in four categories (<25; 25–29; 30–39; 40+), dichotomous UK born and self-reported sexual identity.
Table 2 Prevalence of sexual behaviour measures among 1340 MSM who reported anal or vaginal sex in the past 3 months
MSM reporting anal or vaginal sex in the past 3 months (N=1340)
n (%) 95% CI
CLS with one or more partners (past 3 months) 853 (63.7) 61.0–66.2
CLS with two or more partners (past 3 months) 430 (32.1) 29.6–34.6
CLS with unknown/HIV-positive status partner(s)a (past 3 months) 474 (35.4) 32.9–38.0
Receptive CLS with unknown status partner(s)b (past 3 months) 187 (14.0) 12.2–15.9
Self-reported bacterial STI diagnosis (past year) 423 (31.6) 29.1–34.1
PEP use (past year) 207 (15.5) 13.6–17.5
Eleven or more new sexual partners (past year) 483 (36.0) 33.5–38.7
Group sex (past 3 months) 496 (37.0) 34.5–39.6
CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; STI, sexually transmitted infection.
a. Men who reported no CLS partners of unknown HIV status, and only one HIV positive CLS partner who was a long-term partner and with whom they ‘thought the risks of catching HIV
were low because their partner was taking ART’ were not counted as positive for this measure.
b. Includes men who reported always being the receptive partner and those who reported being sometimes the receptive and sometimes insertive partner. Only men who reported that
they did not know the HIV status of any of their partners could be included, as for those who reported knowing some or all of their partners’ HIV status, it was not possible to
distinguish whether this was the HIV-positive partner with whom the participant had insertive or receptive CLS.
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lifestyle factors. However, depressive symptoms were not associated
with having a higher number of new sexual partners or group sex.
Burden of depressive symptoms among MSM and
associated factors
Minority stress theory and masculine socialisation stress theory
stipulate that gay (and bisexual) men may experience high levels
of psychological distress as a result of conflict produced between
mainstream social norms and minority values. Social pressure to
conform to traditional gender-normative behaviour may increase
shaming and victimisation of men in sexual minority groups, and
risk of internalised homophobia, adverse mental health outcomes,
violence-prone partnerships and/or substance use for these
men.33,34 A recent systematic review of mainly US or Canadian
studies reported elevated levels of depression among sexual
minorities compared with heterosexual individuals,35 but there is
less evidence from the UK. In this study, the prevalence of
depressive symptoms among MSM in 2013–2014 was 12%. A
general population-based survey in England in 2007–2008 found
the prevalence of depressive symptoms to be 7% by the same
definition (PHQ-9≥10) and this figure included women, among
whom rates of depression are often higher. This suggests
prevalence may be somewhat higher among MSM compared
with other men, but other sociodemographic factors may con-
found this comparison.36 There are a number of other probability-
based sample and general population-based survey studies that
have collected information on depression among individuals in
the UK; however, none have incorporated the PHQ-9.37–42 In the
most recent (2010–2012) British National Survey of Sexual
Attitudes and Lifestyles (NATSAL), a shortened version of the
PHQ-9 was used (PHQ-2, which includes only the first two
questions): 8.9% (95% CI 5.5–14.3, n/N=17/190) of all MSM,
6.4% (95% CI 3.5–11.7, n/N=7/107) of gay-identified MSM and
8.9% (95% CI 8.1–9.8, n/N=451/5069) of men who reported sex
exclusively with women screened positive for depression.43 By the
same definition (PHQ-2≥3), the prevalence of depression in
MSM included in this AURAH analysis was 9.3%; among all MSM
in AURAH the comparable prevalence was 9.5%.
Studies from the UK, USA and Australia have found that among
MSM, markers of lower socioeconomic status and lower levels
of a supportive network are consistently strongly associated with
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PR, prevalence ratio. P-value
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with high self-efficacy for
sexual safety (independent
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Dependent variable: 
CLS with 1+ partners (past 3 months)
(n=853; 63.7%) 
CLS with 2+ partners (past 3 months)
(n=430; 32.1%) 
CLS with unknown/HIV+ partner(s)a
(past 3 months)
(n=474; 35.4%) 
Receptive CLS with unknown status
partner(s) (past 3 months)
(n=187; 14.0%) 
Bacterial STI diagnosis (past year)
(n=423; 31.6%) 
PEP use (past year)
(n=207; 15.5%) 
11+ new sexual partners
(past year)
(n=483; 36.0%) 
Group sex (past 3 months)
(n=496; 37.0%) 
Unadjusted prevalence ratio (N=1340)
Prevalence ratio adjusted for: age, UK bornb, sexual identityb, university education, ongoing relationship status,
and study region (N=1316) 
Prevalence ratio adjusted for above sociodemographic factors plus smoking, higher-risk drinking, and
number of recreational drugs used (N=1316) 
Fig. 2 Unadjusted and adjusted associations of high self-efﬁcacy for sexual safety with sexual behaviours among 1340 MSM who reported anal or
vaginal sex in the past 3 months.
CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; STI, sexually transmitted infection.
a. Excludes men who reported no CLS partners of unknown HIV status, and only one HIV positive CLS partner who was a long-term partner and with
whom they ‘thought the risks of catching HIV were low because their partner was taking ART’.
b. The model was ﬁtted to include age in four categories (,25; 25–29; 30–39; 40+), dichotomous UK born and self-reported sexual identity.
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symptoms of depression.44–46 Similarly, in this study these factors were
among the strongest correlates of depressive symptoms, sug‐
gesting a critical role of socioeconomic hardship in poor mental health
among UK MSM, as has been found in the general population.42,47,48
Younger age and recreational drug use were associated with
depressive symptoms among MSM in AURAH, as has been found
in other studies.44,46 The prevalence of depressive symptoms was
twice as high in men reporting a bisexual (or other plurisexual)
identity compared with a gay sexual identity (22.1% v. 11.4%,
respectively), a finding that has also been reported in other
studies.46,49 This may reflect higher levels of social support available
in a more established and potentially more cohesive community,
such as the gay community. Bisexual men may be even more
vulnerable to isolation as a sexual minority. Low levels of disclosure
of sexual orientation to work colleagues, smoking and higher risk
alcohol use were also associated with depressive symptoms.
Depressive symptoms and sexual behaviour
To date, two European studies have investigated the relationship
between symptoms of depression and sexual behaviour among MSM.
In a UK GUM clinic sample of 123 MSM in 1999, a higher
prevalence of depressive symptoms (Hospital Anxiety and Depres-
sion Score (HADS) ≥11) was observed among men who reported
CLS with an HIV-positive or unknown status partner v. other men
(χ2 test 13.6% v. 2.7%, based on eight cases of depression only).3
In a Belgian volunteer and online sample of 591 HIV-negative
MSM who reported anal sex with a casual partner (2008), de‐
pressive symptoms (CES-D >21) were associated with CLS
(odds ratio (OR) 1.66, 95% CI 1.16–2.37; P=0.006) in unadjusted
analysis.5 In US studies, the association between depressive
symptoms and sexual risk among MSM has been more consis-
tently demonstrated among samples where the vast majority of
men reported recent sex and recreational drug use (Project MIX
and Frontiers in Prevention7,9), compared with samples which
included a higher proportion of men who did not report recent
sex (Urban Men’s Health Study and Sex and Love Study15,21).
It has been suggested that in the former samples, men may have
been more likely to have an externalised response to depressive
symptoms (such as cognitive escape) rather than an internalised
response such as withdrawal.7 This may in part explain why a
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condom use (independent
variable) 
Unadjusted prevalence ratio (N=1340)
Prevalence ratio adjusted for: age, UK bornb, sexual identityb, university education, ongoing relationship status,
and study region (N=1316) 
Prevalence ratio adjusted for above sociodemographic factors plus smoking, higher-risk drinking, and
number of recreational drugs used (N=1316)
Fig. 3 Unadjusted and adjusted associations of ﬁnding it difﬁcult to negotiate condom use with sexual behaviours among 1340 MSM who reported
anal or vaginal sex in the past 3 months.
CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; STI, sexually transmitted infection.
a. Excludes men who reported no CLS partners of unknown HIV status, and only one HIV positive CLS partner who was a long-term partner and with
whom they ‘thought the risks of catching HIV were low because their partner was taking ART’.
b. The model was ﬁtted to include age in four categories (,25; 25–29; 30–39; 40+), dichotomous UK born and self-reported sexual identity.
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strong relationship was observed in this study among a sexually
active GUM clinic sample.
Depression, alcohol and drug use and sexual behaviour
Our findings suggest that the link between depression and CLS
may in part be confounded by higher levels of drug or alcohol use
among those with depression, but drug and alcohol use are
unlikely to solely explain this relationship. It has been further
stipulated in syndemic theory that it is the synergistic interactions
of two or more co-occurring psychosocial health problems, such
as depression, drug use, childhood sexual abuse and intimate
partner violence, that compound the risk of HIV infection among
MSM.21 Measurement of these factors together with markers of
certain personality traits (sensation seeking and sexual compul-
sivity) would be useful in further studies.
Self-efficacy for sexual safety
Our findings suggest that low self-efficacy for sexual safety and
difficulty negotiating condom use may be potential mechanisms
through which depression leads to CLS, which may explain why a
relationship was observed with CLS measures but not higher
partner numbers. The fact that men who reported depressive
symptoms were more likely to report PEP use suggests that
although depression may impair discussion or negotiation of safe
sex practices, there is still an overarching desire to be safe and
protect oneself after this interaction is over.
Symptoms and treatment for depression in relation to
sexual risk
In this study, there was limited evidence to imply that sucessful
treatment of depression (reporting treatment, but negative for
depressive symptoms according to PHQ-9) may reduce sexual risk.
However, the extent to which this question can be addressed given
the cross-sectional design of the study is limited, and inference may
be complicated by a number of factors including severity
of symptoms before treatment, type, duration and frequency of
treatment, timing of treatment in relation to symptoms, the
presence of other psychological conditions and sensitivity of the
PHQ-9 in capturing all cases of depressive symptoms. There does
appear to be some evidence of potential undertreatment of possible
clinically significant depressive conditions.
Strengths and limitations
Strengths of this study include the large sample size and the fact
that only men who reported sex in the past 3 months were
included in analysis. This is important, as in some men depression
may result in lowered libido and lack of sexual activity. In terms of
limitations, the prevalence of depression and associations with
sexual behaviour may have differed among the 40% of individuals
approached who did not complete the questionnaire. Further-
more, the cross-sectional methodology used in this study prohibits
us from making inferences about causality. In particular, the
PHQ-9 inquires about symptoms during the previous 2 weeks,
Table 3 Unadjusted and adjusted associations of categories of symptoms of depression and medical treatment or therapy for depression
with CLS measures in the past 3 months, among 1340 MSM who reported anal or vaginal sex in the past 3 months
N=1340 MSM reporting sex in the past 3 months
Dependent variable
Depressive symptoms
(PHQ-9≥10)
Receiving treatment
for depression N (%)
%
Pa
Unadjusted PR (95% CI)
Pb
Adjusted PR (95% CI)
Pb
CLS with one or more partners Yes
Yes
No
No
Yes
No
Yes
No
48 (3.6)
118 (8.8)
75 (5.6)
1099 (82.0)
81.3%
72.0%
68.0%
61.7%
0.006
1.32 (1.14, 1.52)
1.17 (1.03, 1.32)
1.10 (0.94, 1.30)
1
<0.001
1.26 (1.08, 1.46)
1.30 (1.02, 1.30)
1.06 (0.90, 1.24)
1
0.006
CLS with two or more partners Yes
Yes
No
No
Yes
No
Yes
No
48 (3.6)
118 (8.8)
75 (5.6)
1099 (82.0)
54.2%
40.7%
40.0%
29.7%
<0.001
1.83 (1.39, 2.41)
1.37 (1.08, 1.74)
1.35 (1.01, 1.81)
1
<0.001
1.65 (1.23, 2.21)
1.37 (1.08, 1.75)
1.35 (1.01, 1.80)
1
0.001
CLS with unknown/HIV-positive
status partner(s)c
Yes
Yes
No
No
Yes
No
Yes
No
48 (3.6%)
118 (8.8%)
75 (5.6%)
1099 (82.0%)
54.2%
49.2%
50.7%
32.0%
<0.001
1.69 (1.29, 2.22)
1.53 (1.25, 1.88)
1.58 (1.25, 2.01)
1
<0.001
1.50 (1.11, 2.02)
1.48 (1.20, 1.82)
1.57 (1.23, 2.00)
1
<0.001
Receptive CLS with an unknown
status partner
Yes
Yes
No
No
Yes
No
Yes
No
48 (3.6)
118 (8.8)
75 (5.6)
1099 (82.0)
25.0%
22.0%
24.0%
11.9%
<0.001
2.10 (1.25, 3.51)
1.85 (1.27, 2.69)
2.01 (1.30, 3.11)
1
<0.001
1.68 (0.94, 2.99)
1.71 (1.16, 2.52)
2.08 (1.34, 3.21)
1
0.001
Self-reported bacterial STI
diagnosis (past year)
Yes
Yes
No
No
Yes
No
Yes
No
48 (3.6)
118 (8.8)
75 (5.6)
1099 (82.0)
35.4%
44.9%
33.3%
29.9%
0.009
1.19 (0.80, 1.76)
1.50 (1.21, 1.87)
1.12 (0.80, 1.56)
1
0.004
1.34 (0.91, 1.96)
1.52 (1.21, 1.92)
1.12 (0.81, 1.55)
1
0.003
PEP use (past year) Yes
Yes
No
No
Yes
No
Yes
No
48 (3.6)
118 (8.8)
75 (5.6)
1099 (82.0)
25.0%
22.9%
17.3%
14.1%
0.018
1.77 (1.06, 2.96)
1.62 (1.13, 2.33)
1.23 (0.73, 2.06)
1
0.014
2.05 (1.21, 3.47)
1.78 (1.22, 2.58)
1.28 (0.77, 2.12)
1
0.002
Note: Adjusted models – age (in four categories: <25, 25–29, 30–39 or ≥40 years), UK born (yes or no/missing), sexual identity (gay or bisexual/straight), university education (yes or no/
missing), ongoing relationship status (yes or no/missing) and study region (London, South or other).
CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; PHQ, Patient Health Questionnaire; PR, prevalence ratio; STI, sexually transmitted infection.
a. Pearson’s χ2 test.
b. Wald test from modified Poisson regression.
c. Excludes men who reported no CLS partners of unknown HIV status, and only one HIV positive CLS partner who was a long-term partner and with whom they ‘thought the risks of
catching HIV were low because their partner was taking ART’.
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whereas the recall periods for sexual behaviour were longer (past 3
months or past year). Because depression questionnaires aim to
provide a diagnostic measure of a chronic mental health condi-
tion, it is not unreasonable to assume that in many participants
depression may have preceded the recent sexual behaviour
reported. The strong adjusted associations found between depres-
sive symptoms and CLS, and the evidence for low self-efficacy as a
mechanism for these relationships, provide some support in
favour of a causal association. Furthermore, there appeared to be
some evidence of a gradient in CLS prevalence with more severe
depressive symptoms. On the other hand, the elevated prevalence
of some CLS measures among men who reported treatment for
depression but were not PHQ-9 positive (i.e. apparently successful
treatment) could be regarded as evidence that causality, at least to
some extent, may operate in the other direction. Finally, our study
is important in the context of GUM services but it does not
necessarily allow us to generalise to all MSM in the UK.
Implications
Our findings suggest the need for an integrated sexual health
approach. Screening for depressive symptoms using brief instru-
ments in sexual health services may be useful in identifying
individuals who could be offered referral for potential interventions.
Socioeconomic advantage and supportive networks may be critical
factors for mental health. Care should be taken to include men with
plurisexual identities in efforts to promote supportive networks
and manage symptoms of depression. In parallel, integration of
(or good linkage to) substance use services could also play a role in
management of depression and reduction of sexual risk.
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